Furthermore, combining anti-MDA5 IgG1 with CRPhigh >8 mg/l [AUC 0.79 (95% CI: 0.67, 0.90)], anti-Ro52 antibody [AUC 0.72 (95% CI: 0.60, 0.84)] and SFhigh >300 ng/ml [AUC 0.73 (95% CI: 0.60, 0.85)] can also enhance the predictive accuracy for RP-ILD (Fig. 3A). This evidence concerns the gene TRIM21 and interstitial lung disease.